Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
30
06
2021
accepted:
28
02
2022
pubmed:
13
4
2022
medline:
21
5
2022
entrez:
12
4
2022
Statut:
ppublish
Résumé
Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination or by repeated infusions of bnAbs. In this study, we administered a recombinant bicistronic adeno-associated virus (AAV8) vector coding for both the light and heavy chains of the potent broadly neutralizing HIV-1 antibody VRC07 (AAV8-VRC07) to eight adults living with HIV. All participants remained on effective anti-retroviral therapy (viral load (VL) <50 copies per milliliter) throughout this phase 1, dose-escalation clinical trial ( NCT03374202 ). AAV8-VRC07 was given at doses of 5 × 10
Identifiants
pubmed: 35411076
doi: 10.1038/s41591-022-01762-x
pii: 10.1038/s41591-022-01762-x
pmc: PMC9876739
mid: NIHMS1863669
doi:
Substances chimiques
Antibodies, Neutralizing
0
Broadly Neutralizing Antibodies
0
HIV Antibodies
0
Banques de données
ClinicalTrials.gov
['NCT03374202']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1022-1030Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Organisme : NIAID NIH HHS
ID : K22 AI102769
Pays : United States
Investigateurs
Charla Andrews
(C)
Anita Arthur
(A)
Seemal F Awan
(SF)
Allison Beck
(A)
Eugeania Burch
(E)
Maria C Burgos Florez
(MC)
Nina M Berkowitz
(NM)
Eli A Boritz
(EA)
Kevin Carlton
(K)
Cora T Cartagena
(CT)
Christina Carter
(C)
Grace L Chen
(GL)
Pamela Costner
(P)
Jennifer Cunningham
(J)
Daniel C Douek
(DC)
Aba M Eshun
(AM)
Catina Evans
(C)
Renunda Hicks
(R)
Katherine V Houser
(KV)
Justine Jones
(J)
Brenda Larkin
(B)
Lam Le
(L)
Floreliz Mendoza
(F)
Stephen Migueles
(S)
John Misasi
(J)
Thuy A Nguyen
(TA)
Abidemi Ola
(A)
Karen Parker
(K)
Iris Pittman
(I)
La' Shawn Requilman
(LS)
Ro Shauna Rothwell
(RS)
Gretchen L Schieber
(GL)
Jamie Saunders
(J)
Sandra Sitar
(S)
Colin Tran
(C)
Olga Trofymenko
(O)
Olga Vasilenko
(O)
Sana Waheed
(S)
Lingshu Wang
(L)
Xiaolin Wang
(X)
William Whalen
(W)
Pernell Williams
(P)
Richard L Wu
(RL)
Kathy Zephir
(K)
Informations de copyright
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Fuchs, S. P. & Desrosiers, R. C. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol. Ther. Methods Clin. Dev. 3, 16068 (2016).
pubmed: 28197421
pmcid: 5289440
doi: 10.1038/mtm.2016.68
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
pubmed: 19843557
doi: 10.1056/NEJMoa0908492
Gift, S. K., Leaman, D. P., Zhang, L., Kim, A. S. & Zwick, M. B. Functional stability of HIV-1 envelope trimer affects accessibility to broadly neutralizing antibodies at its apex. J. Virol. 91, e01216–17 (2017).
pubmed: 28978711
pmcid: 5709597
doi: 10.1128/JVI.01216-17
Torrents de la Pena, A. et al. Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization. Cell Rep. 20, 1805–1817 (2017).
pubmed: 28834745
pmcid: 5590011
doi: 10.1016/j.celrep.2017.07.077
Klein, J. S. & Bjorkman, P. J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6, e1000908 (2010).
pubmed: 20523901
pmcid: 2877745
doi: 10.1371/journal.ppat.1000908
Schiller, J. & Chackerian, B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 10, e1004254 (2014).
pubmed: 25101974
pmcid: 4125284
doi: 10.1371/journal.ppat.1004254
Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).
pubmed: 25988889
pmcid: 4834917
doi: 10.1038/ni.3158
Pancera, M. et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1–V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20, 804–813 (2013).
pubmed: 23708607
pmcid: 4046252
doi: 10.1038/nsmb.2600
Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).
pubmed: 12646921
doi: 10.1038/nature01470
Hartley, O., Klasse, P. J., Sattentau, Q. J. & Moore, J. P. V3: HIV’s switch-hitter. AIDS Res Hum. Retroviruses 21, 171–189 (2005).
pubmed: 15725757
doi: 10.1089/aid.2005.21.171
Bonsignori, M. et al. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 275, 145–160 (2017).
pubmed: 28133802
pmcid: 5302796
doi: 10.1111/imr.12509
Korber, B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19–42 (2001).
pubmed: 11714622
doi: 10.1093/bmb/58.1.19
Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108–1121 (2016).
pubmed: 27851912
pmcid: 5770152
doi: 10.1016/j.immuni.2016.10.027
Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012).
pubmed: 23151583
pmcid: 4854285
doi: 10.1038/nature11544
Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268–3277 (2012).
pubmed: 23115339
pmcid: 3511153
Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624–17629 (2014).
pubmed: 25422458
pmcid: 4267403
doi: 10.1073/pnas.1415789111
Wu, X. HIV broadly neutralizing antibodies: VRC01 and beyond. Adv. Exp. Med. Biol. 1075, 53–72 (2018).
pubmed: 30030789
doi: 10.1007/978-981-13-0484-2_3
Liu, J. et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353, 1045–1049 (2016).
pubmed: 27540005
pmcid: 5237379
doi: 10.1126/science.aag0491
Mascola, J. R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).
pubmed: 10196297
pmcid: 104180
doi: 10.1128/JVI.73.5.4009-4018.1999
Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669–12682 (2014).
pubmed: 25142607
pmcid: 4248941
doi: 10.1128/JVI.02213-14
Saunders, K. O. et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895–5903 (2015).
pubmed: 25787288
pmcid: 4442454
doi: 10.1128/JVI.00210-15
Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015).
pubmed: 25855300
pmcid: 4890714
doi: 10.1038/nature14411
Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
pubmed: 26702094
doi: 10.1126/scitranslmed.aad5752
Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).
pubmed: 30258136
pmcid: 6166473
doi: 10.1038/s41586-018-0531-2
Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev. Immunol. 34, 635–659 (2016).
pubmed: 27168247
pmcid: 6034635
doi: 10.1146/annurev-immunol-041015-055515
Kwong, P. D., Mascola, J. R. & Nabel, G. J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1, a007278 (2011).
pubmed: 22229123
pmcid: 3234457
doi: 10.1101/cshperspect.a007278
Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81–84 (2011).
pubmed: 22139420
pmcid: 3253190
doi: 10.1038/nature10660
Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901–906 (2009).
pubmed: 19448633
pmcid: 2723177
doi: 10.1038/nm.1967
Sharon, D. & Kamen, A. Advancements in the design and scalable production of viral gene transfer vectors. Biotechnol. Bioeng. 115, 25–40 (2018).
pubmed: 28941274
doi: 10.1002/bit.26461
Daya, S. & Berns, K. I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21, 583–593 (2008).
pubmed: 18854481
pmcid: 2570152
doi: 10.1128/CMR.00008-08
Duan, D. et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72, 8568–8577 (1998).
pubmed: 9765395
pmcid: 110267
doi: 10.1128/JVI.72.11.8568-8577.1998
Nowrouzi, A. et al. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol. Ther. 20, 1177–1186 (2012).
pubmed: 22453768
pmcid: 3369298
doi: 10.1038/mt.2012.47
Penaud-Budloo, M. et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J. Virol. 82, 7875–7885 (2008).
pubmed: 18524821
pmcid: 2519600
doi: 10.1128/JVI.00649-08
Brady, J. M., Baltimore, D. & Balazs, A. B. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol. Rev. 275, 324–333 (2017).
pubmed: 28133808
pmcid: 5300685
doi: 10.1111/imr.12478
Schnepp, B. C. & Johnson, P. R. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr. Opin. HIV AIDS 9, 250–256 (2014).
pubmed: 24638019
pmcid: 4117238
doi: 10.1097/COH.0000000000000056
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381–390 (2009).
pubmed: 19133809
doi: 10.1086/595830
Srivastava, A. In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 21, 75–80 (2016).
pubmed: 27596608
pmcid: 5138125
doi: 10.1016/j.coviro.2016.08.003
Balazs, A. B. et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20, 296–300 (2014).
pubmed: 24509526
pmcid: 3990417
doi: 10.1038/nm.3471
Saunders, K. O. et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J. Virol. 89, 8334–8345 (2015).
pubmed: 26041300
pmcid: 4524228
doi: 10.1128/JVI.00908-15
Welles, H. C. et al. Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog. 14, e1007395 (2018).
pubmed: 30517201
pmcid: 6296672
doi: 10.1371/journal.ppat.1007395
Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575 e565 (2019).
pubmed: 30850342
pmcid: 6457122
doi: 10.1016/j.immuni.2019.02.005
Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230–e239 (2019).
pubmed: 30885692
pmcid: 6443625
doi: 10.1016/S2352-3018(19)30003-7
Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589–594 (2004).
pubmed: 15064769
doi: 10.1038/nbt957
Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347 (2006).
pubmed: 16474400
doi: 10.1038/nm1358
Rangarajan, S. et al. AAV5-Factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530 (2017).
pubmed: 29224506
doi: 10.1056/NEJMoa1708483
Jefferis, R. & Lefranc, M. P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1, 332–338 (2009).
pubmed: 20073133
pmcid: 2726606
doi: 10.4161/mabs.1.4.9122
Ledgerwood, J. E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289–301 (2015).
pubmed: 26332605
pmcid: 4636891
doi: 10.1111/cei.12692
Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131–146 (2014).
pubmed: 24291345
doi: 10.1016/j.jim.2013.11.022
Nathwani, A. C. et al. Long-term safety and efficacy of Factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994–2004 (2014).
pubmed: 25409372
pmcid: 4278802
doi: 10.1056/NEJMoa1407309
Lisowski, L., Tay, S. S. & Alexander, I. E. Adeno-associated virus serotypes for gene therapeutics. Curr. Opin. Pharm. 24, 59–67 (2015).
doi: 10.1016/j.coph.2015.07.006
Fuchs, S. P. et al. AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog. 11, e1005090 (2015).
pubmed: 26248318
pmcid: 4527674
doi: 10.1371/journal.ppat.1005090
Fuchs, S. P., Martinez-Navio, J. M., Rakasz, E. G., Gao, G. & Desrosiers, R. C. Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in rhesus monkeys. Mol. Ther. Methods Clin. Dev. 16, 94–102 (2020).
pubmed: 31890736
doi: 10.1016/j.omtm.2019.11.010
Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037–2050 (2016).
pubmed: 27959728
pmcid: 5292134
doi: 10.1056/NEJMoa1608243
Cale, E. M. et al. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J. Clin. Invest. 130, 3299–3304 (2020).
pubmed: 32182219
pmcid: 7259993
doi: 10.1172/JCI134395
Crowell, T. A. et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 6, e297–e306 (2019).
pubmed: 31000477
pmcid: 6693657
doi: 10.1016/S2352-3018(19)30053-0
Cunningham, C. K. et al. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. J. Infect. Dis. 222, 628–636 (2020).
pubmed: 31681963
doi: 10.1093/infdis/jiz532
Riddler, S. A. et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect. Dis. 5, ofy242 (2018).
pubmed: 30364428
pmcid: 6195652
doi: 10.1093/ofid/ofy242
Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).
pubmed: 29364886
pmcid: 5783347
doi: 10.1371/journal.pmed.1002493
Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 6, e667–e679 (2019).
pubmed: 31473167
doi: 10.1016/S2352-3018(19)30181-X
Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185–191 (2017).
pubmed: 28092665
pmcid: 5467219
doi: 10.1038/nm.4268
Fang, J. et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584–590 (2005).
pubmed: 15834403
doi: 10.1038/nbt1087
Zhou, T. et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245–258 (2013).
pubmed: 23911655
pmcid: 3985390
doi: 10.1016/j.immuni.2013.04.012
Fang, J. et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol. Ther. 15, 1153–1159 (2007).
pubmed: 17375065
doi: 10.1038/sj.mt.6300142
Schambach, A. et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641–645 (2006).
pubmed: 16355114
doi: 10.1038/sj.gt.3302698
Casazza, J. P. et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829–1840 (2013).
pubmed: 23482645
pmcid: 3654747
doi: 10.1093/infdis/jit098
Prabhakaran, M. et al. A sensitive method to quantify HIV-1 antibodies in mucosal samples. J. Immunol. Methods 491, 112995 (2021).
pubmed: 33582148
doi: 10.1016/j.jim.2021.112995
Seaman, M. S. et al. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. J. Immunol. Methods 479, 112736 (2020).
pubmed: 31917969
pmcid: 7103754
doi: 10.1016/j.jim.2020.112736
Pandey, J. P. et al. Immunoglobulin genes and immunity to HSV1 in Alzheimer’s disease. J. Alzheimers Dis. 70, 917–924 (2019).
pubmed: 31306125
doi: 10.3233/JAD-190265
Schanfield, M. & van Logem, E. in Handbook of Experimental Immunology Vol. 94 (ed. Weir, D.) 1–18 (Blackwell, 1986).